A recent study using advanced genomic analyses and single-cell imaging reported that mutational signature 3 (a specific mutational signature reflecting defective HR) and positive immune score (a surrogate of interferon-primed exhausted CD8+ T-cells in the tumor microenvironment) determined response to niraparib plus pembrolizumab in patients with platinum-resistant ovarian cancer enrolled in the TOPACIO trial (66). Here, CD8A is linked to neoplasm.